Role of oxidized low-density lipoprotein in renal disease

Current Opinion in Nephrology and Hypertension

Volumn 11, Issue 3, 2002, Pages 287-293

  Heeringa, Peter ^a   Tervaert, Jan W Cohen ^a  

^a MAASTRICHT UNIVERSITY   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIBODY; LOW DENSITY LIPOPROTEIN; MONOCLONAL ANTIBODY;

ATHEROSCLEROSIS; AUTOIMMUNITY; DISEASE COURSE; HUMAN; KIDNEY DISEASE; KIDNEY FAILURE; LIPID OXIDATION; NONHUMAN; OXIDATIVE STRESS; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; IMMUNOLOGY; METABOLISM; OXIDATION REDUCTION REACTION;

AUTOANTIBODIES; HUMANS; KIDNEY DISEASES; LIPOPROTEINS, LDL; OXIDATION-REDUCTION;

EID: 1842856219     PISSN: 10624821     EISSN: None     Source Type: Journal    
DOI: 10.1097/00041552-200205000-00004     Document Type: Review

References (72)

1. Lipids and progression of renal disease: Role of modified low density lipoprotein and lipoprotein(a)
2. The oxidative modification hypothesis of atherosclerosis: Does it hold for humans?
3. Atherosclerosis: An inflammatory disease
4. Iron and copper promote modification of low density lipoprotein by human arterial smooth muscle cells in culture
5. Superoxide-mediated modification of low density lipoprotein by arterial smooth muscle cells
6. Lipoprotein oxidation and lipoprotein-induced cytotoxicity
7. Oxidants and antioxidants in the pathogenesis of atherosclerosis: Implications for the oxidized low density lipoprotein hypothesis
8. The oxidation of lipoproteins by monocytes-macrophages: Biochemical and biological mechanisms
9. Low density lipoprotein undergoes oxidative modification in vivo
10. Malondialdehyde-modified low density lipoproteins in patients with atherosclerotic disease
11. Circulating oxidized LDL is a useful marker for identifying patients with coronary artery disease
12. Elevated levels of oxidized low density lipoprotein show a positive relationship with the severity of acute coronary syndromes
13. Lipoproteins in normal and atherosclerotic aorta
14. Dietary antioxidant inhibits lipoprotein oxidation and renal injury in experimental focal segmental glomerulosclerosis
15. Identification of oxidized low density lipoprotein in human renal biopsies
16. Oxidized low-density lipoprotein in experimental focal glomerulosclerosis
17. Lipid peroxidation in human proteinuric disease
18. Oxidative modification of low-density lipoproteins and the outcome of renal allografts at 1 1/2 years
19. Myeloperoxidase-generated oxidants and atherosclerosis
20. Human low density lipoprotein as a target of hypochlorite generated by myeloperoxidase
21. Presence of hypochlorite-modified proteins in human atherosclerotic lesions
22. Immunological evidence for hypochlorite-modified proteins in human kidney
23. Immunohistochemical evidence for the myeloperoxidase/H202/halide system in human atherosclerotic lesions: Colocalization of myeloperoxidase and hypochlorite-modified proteins
24. The role of oxidized lipoproteins in atherogenesis
25. Mildly oxidized low density lipoprotein activates multiple apoptotic signaling pathways in human coronary cells
26. Oxidized LDL-induced injury and apoptosis in atherosclerosis: Potential roles for oxysterols
27. Influence of caveolin, cholesterol, and lipoproteins on nitric oxide synthase: Implications for vascular disease
28. Hypochlorite-modified low density lipoprotein inhibits nitric oxide synthesis in endothelial cells via an intracellular dislocalization of endothelial nitric-oxide synthase
29. High density lipoprotein prevents oxidized low density lipoprotein-induced inhibition of endothelial nitric-oxide synthase localization and activation in caveolae
30. Human mesangial cells express inducible macrophage scavenger receptor
31. Oxidation of low-density lipoproteins by rat mesangial cells and the interaction of oxidized low-density lipoproteins with rat mesangial cells in vitro
32. Detection of cell death of cultured mouse mesangial cells induced by oxidized low-density lipoprotein
33. Oxidative modification of low-density lipoprotein enhances the murine mesangial cell cytokines associated with monocyte migration, differentiation, and proliferation
34. Oxidative modification of low-density lipoprotein enhances mesangial cell protein synthesis and gene expression of extracellular matrix proteins
35. Effect of lipoproteins on mesangial cell proliferation
36. Low-density lipoprotein-induced expression of interleukin-6, a marker of human mesangial cell inflammation: Effects of oxidation and modulation by lovastatin
37. Native and modified LDL activate extracellular signal-regulated kinases in mesangial cells
38. Immune responses to oxidative neoepitopes on LDL and phospholipids modulate the development of atherosclerosis
39. ApoE-deficient mice are a model of lipoprotein oxidation in atherogenesis: Demonstration of oxidation-specific epitopes in lesions and high titers of autoantibodies to malondialdehyde-lysine in serum
40. Immunological evidence for the presence of advanced glycosylation end products in atherosclerotic lesions of euglycemic rabbits
41. Antibodies to oxidized LDL predict coronary artery disease in type 1 diabetes: A nested case-control study from the Pittsburgh Epidemiology of Diabetes Complications Study
42. Anti-oxidized low-density lipoprotein antibodies in patients with coronary heart disease and normal healthy volunteers
43. Antibody against oxidized low-density lipoprotein predicting myocardial infarction
44. Autoantibody against oxidised LDL and progression of carotid atherosclerosis
45. T lymphocytes from human atherosclerotic plaques recognize oxidized low density lipoprotein
46. Autoantibodies against oxidized LDL do not predict atherosclerotic vascular disease in non-insulin-dependent diabetes mellitus
47. Association of serum vitamin levels, LDL susceptibility to oxidation, and autoantibodies against MDA-LDL with carotid atherosclerosis: A case-control study
48. Enhanced LDL oxidation in uremic patients: An additional mechanism for accelerated atherosclerosis?
49. Antibodies against oxidized low-density lipoproteins in systemic sclerosis
50. Patients with systemic vasculitis have increased levels of autoantibodies against oxidized LDL
51. Antibodies to oxidised LDL
52. Crossreaction between antibodies to oxidised low-density lipoprotein and to cardiolipin in systemic lupus erythematosus
53. Risk factors for cardiovascular disease in systemic lupus erythematosus
54. The level of autoantibodies against oxidized LDL is not associated with the presence of coronary heart disease or diabetic kidney disease in patients with non-insulin-dependent diabetes mellitus
55. Autoantibodies against oxidized LDL in chronic renal failure: Role of renal function, diet, and lipids
56. Endothelial dysfunction in chronic renal failure: Roles of lipoprotein oxidation and pro-inflammatory cytokines
57. Anti-oxidized low-density-lipoprotein (OxLDL) antibodies in systemic lupus erythematosus with and without antiphospholipid syndrome
58. Hyperimmunization of apo-E-deficient mice with homologous malondialdehyde low-density lipoprotein suppresses early atherogenesis
59. Immunization of LDL receptor-deficient mice with homologous malondialdehyde-modified and native LDL reduces progression of atherosclerosis by mechanisms other than induction of high titers of antibodies to oxidative neoepitopes
60. Immunization of low density lipoprotein (LDL) receptor-deficient rabbits with homologous malondialdehyde-modified LDL reduces atherogenesis
61. Effect of immunization with homologous LDL and oxidized LDL on early atherosclerosis in hypercholesterolemic rabbits
62. Induction of neonatal tolerance to oxidized lipoprotein reduces atherosclerosis in ApoE knockout mice
63. The role of adaptive immunity in atherosclerosis
64. Detection of activated T lymphocytes in the human atherosclerotic plaque
65. The role of interleukin 12 in the development of atherosclerosis in ApoE-deficient mice
66. Exogenous interferon-gamma enhances atherosclerosis in apolipoprotein E -/- mice
67. In vivo downregulation of T helper cell 1 immune responses reduces atherogenesis in apolipoprotein E-knockout mice
68. Cloning of monoclonal autoantibodies to epitopes of oxidized lipoproteins from apolipoprotein E-deficient mice. Demonstration of epitopes of oxidized low density lipoprotein in human plasma
69. Antiphospholipid antibodies are directed against epitopes of oxidized phospholipids: Recognition of cardiolipin by monoclonal antibodies to epitopes of oxidized low density lipoprotein
70. Monoclonal autoantibodies specific for oxidized phospholipids or oxidized phospholipid-protein adducts inhibit macrophage uptake of oxidized low-density lipoproteins
71. Natural antibodies with the T15 idiotype may act in atherosclerosis, apoptotic clearance, and protective immunity
72. Human-derived anti-oxidized LDL autoantibody blocks uptake of oxidized LDL by macrophages and localizes to atherosclerotic lesions in vivo